title: Pancreatic cancer in the older patient.
abstract: Pancreatic cancer is a disease seen predominantly in elderly patients. Compared to younger patients, older patients are more likely to present with early-stage disease and, therefore, may be candidates for aggressive local treatment. Little published information exists on treatment outcomes for elderly patients with potentially resectable disease or those with locally advanced or metastatic pancreatic cancer. The limited information available suggests that elderly patients are as likely to benefit from surgery, radiation, and chemotherapy as younger patients. Despite this apparent benefit, elderly patients appear to have a worse long-term outcome. This may be due to the failure to offer them aggressive treatment or to comorbid conditions. Nevertheless, further studies need to be conducted in this area, and greater emphasis needs to be placed on including elderly patients in clinical trials. For elderly patients with terminal disease, there should be better use of palliative measures that may be of benefit. Each of these issues is discussed in detail.
authors.affiliation: Mayo Graduate School of Medicine, Rochester, Minnesota 55905, USA.
authors.forename: S D
authors.initials: SD
authors.lastname: Jacobson
authors.forename: S R
authors.initials: SR
authors.lastname: Alberts
authors.forename: M J
authors.initials: MJ
authors.lastname: O'Connell
mesh_terms: D000367:Age Factors; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D002779:Cholestasis / Q000209:etiology / Q000628:therapy; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D010146:Pain / Q000209:etiology; D059408:Pain Management; D010166:Palliative Care / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000628:therapy*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine